 |
|
Maximum: 1 CME cr.,
1 AutoAttendance cr.
0 new discussion posts (1 published)
Sign in to view your progression
|
Activity Title: The Impact of COVID-19 on Global Infectious Diseases: 2022 Update
Release Date: January 18, 2022
Estimated Time to Complete Activity: 70 minutes
Statement of Need:
With the world’s attention and resources focused towards COVID-19 prevention and response efforts, we have witnessed widespread disruptions to HIV, TB, and malaria service delivery programs globally with shortages in medical supplies, treatments, and diagnostics. As observed during previous crises, the indirect morbidity and mortality effects of the ongoing COVID-19 pandemic may be as important as the direct effects of the pandemic itself. Existing infectious diseases management and prevention programs have been hit by lockdowns, changing funding priorities, and re-allocation of staff and resources. This webinar is a follow-up to the webinar published on October 7, 2020, when Lulu Bravo and Francoise Venter discussed COVID-19’s early impact on childhood vaccinations and the provision of TB and HIV care during the evolving pandemic. Much data has been collected and analyzed since then to better understand the full impact of the COVID-19 pandemic on the prevention and management of communicable diseases.
Faculty:
Prof. Lulu Bravo
Professor Emeritus University of the Philippines, Manila
Prof. François Venter
Director of Ezintsha, Faculty of Health Sciences, University of the Witwatersrand
Technical Requirements:
This site and its activities are best viewed using the latest versions of the Chrome, Edge, Firefox and Safari browsers. For interactive content, a broadband connection is required. For CME/CE activities featuring audio, you need a sound card and speakers.
Our activities may require JavaScript to be enabled on your computer. If you are having difficulty viewing pop-up windows, click here for instructions on enabling JavaScript.
Contact Information
If you have questions about this CME activity, please contact The International Society for Infectious Diseases at info@isid.org.
For technical support issues, please contact Multilearning at support@multilearning.com
Upon completion of this module, participants will be able to:
- Recognize the widespread disruptions to HIV, TB, and malaria service delivery programs globally during the pandemic
- Discuss how the pandemic affected medical supplies, treatments, and diagnostics.
- Recognize how the indirect morbidity and mortality effects of the ongoing COVID-19 pandemic may be as important as the direct effects of the pandemic itself.
- Discuss how existing infectious diseases management and prevention programs have been hit by lockdowns, changing funding priorities, and re-allocation of staff and resources.
- Discuss the new data that has been collected and analyzed since then to better understand the full impact of the COVID-19 pandemic on the prevention and management of communicable diseases.
The target audience for this module is physicians, nurses, public health officials, researchers, immunization officers, and other health professionals.
Global ID references
Pai M, Kasaeva T, Swaminathan S. Covid-19's Devastating Effect on Tuberculosis Care - A Path to Recovery. N Engl J Med. 2022 Jan 5. doi: 10.1056/NEJMp2118145. Epub ahead of print. PMID: 34986295. https://pubmed.ncbi.nlm.nih.gov/34986295/
WHO: Impact of the COVID-19 pandemic on TB detection and mortality in 2020. 22 March 2021. Technical document. https://www.who.int/publications/m/item/impact-of-the-covid-19-pandemic-on-tb-detection-and-mortality-in-2020
Santoli JM, Lindley MC, DeSilva MB, et al. Effects of the COVID-19 Pandemic on Routine Pediatric Vaccine Ordering and Administration — United States, 2020. MMWR Morb Mortal Wkly Rep 2020;69:591–593. DOI: http://dx.doi.org/10.15585/mmwr.mm6919e2external icon
Shet A, Carr K, Danovaro-Holliday MC, Sodha SV, Prosperi C, Wunderlich J, Wonodi C, Reynolds HW, Mirza I, Gacic-Dobo M, O'Brien KL, Lindstrand A. Impact of the SARS-CoV-2 pandemic on routine immunisation services: evidence of disruption and recovery from 170 countries and territories. Lancet Glob Health. 2022 Feb;10(2):e186-e194. doi: 10.1016/S2214-109X(21)00512-X. Epub 2021 Dec 21. PMID: 34951973; PMCID: PMC8691849. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8691849/
WHO Global Clinical Platform for COVID-19. Clinical features and prognostic factors of COVID-19 in people living with HIV hospitalized with suspected or confirmed SARS-CoV-2 infection. https://apps.who.int/iris/bitstream/handle/10665/342697/WHO-2019-nCoV-Clinical-HIV-2021.1-eng.pdf
HIV references:
WHO: Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach (2021). https://www.who.int/publications/i/item/9789240031593
PREEXPOSURE PROPHYLAXIS FOR THE PREVENTION OF HIV INFECTION IN THE UNITED STATES – 2021 UPDATE. A CLINICAL PRACTICE GUIDELINE. https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf
Commissioners of and collaborators with the International AIDS Society–Lancet Commission on Health and Human Rights. Human rights and fair access to COVID-19 vaccines: the International AIDS Society-Lancet Commission on Health and Human Rights. Lancet. 2021 Apr 24;397(10284):1524-1527. doi: 10.1016/S0140-6736(21)00708-X. Epub 2021 Mar 24. PMID: 33773117; PMCID: PMC7990478. https://pubmed.ncbi.nlm.nih.gov/33773117/
Lazarus JV, Safreed-Harmon K, Kamarulzaman A, Anderson J, Leite RB, Behrens G, Bekker LG, Bhagani S, Brown D, Brown G, Buchbinder S, Caceres C, Cahn PE, Carrieri P, Caswell G, Cooke GS, Monforte AD, Dedes N, Del Amo J, Elliott R, El-Sadr WM, Fuster-Ruiz de Apodaca MJ, Guaraldi G, Hallett T, Harding R, Hellard M, Jaffar S, Kall M, Klein M, Lewin SR, Mayer K, Pérez-Molina JA, Moraa D, Naniche D, Nash D, Noori T, Pozniak A, Rajasuriar R, Reiss P, Rizk N, Rockstroh J, Romero D, Sabin C, Serwadda D, Waters L. Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV. Nat Commun. 2021 Jul 16;12(1):4450. doi: 10.1038/s41467-021-24673-w. PMID: 34272399; PMCID: PMC8285468. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285468/
Hempel S, Ferguson L, Bolshakova M, Yagyu S, Fu N, Motala A, Gruskin S. Frameworks, measures, and interventions for HIV-related internalised stigma and stigma in healthcare and laws and policies: systematic review protocol. BMJ Open. 2021 Dec 9;11(12):e053608. doi: 10.1136/bmjopen-2021-053608. PMID: 34887280; PMCID: PMC8663079. https://bmjopen.bmj.com/content/11/12/e053608.long
Disclosure Policy
In accordance with the EACCME Standards for Commercial Support, the International Society for Infectious Diseases (ISID) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. ISID resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all our educational programs. Furthermore, ISID seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. ISID is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.
Activity Staff Disclosures:
The planners, reviewers, editors, staff, or other members at the International Society for Infectious Diseases who control content have no relevant financial relationships to disclose.
ISID Knowledge Exchange and E-Learning Platform Organizing Committee members are listed here along with Committee members’ disclosure forms.
Faculty Disclosures:
Professor Lulu C. Bravo has no actual or potential conflict of interest in relation to this program/presentation
Professor Francois Venter's disclosures:
Grants/Research Support: Funding from the Bill and Melinda Gates Foundation, SA Medical Research Council, National Institutes for Health, AIDS Funds, Unitaid, Foundation for Innovative New Diagnostics, the Children’s Investment Fund Foundation, USAID.
Drug donations from ViiV Healthcare, Merck and Gilead (for investigator-led clinical studies).
Investigator led studies for Merck and ViiV
Commercial drug studies for Merck
Evaluations of diagnostic devices for various biotech companies
Honoraria/Consultation fees:
Gilead, ViiV, Mylan, Merck, Adcock-Ingram, Aspen, Abbott, Roche, J&J, Virology Education
Moderator Disclosures:
Dr. Afreenish Amir has no actual or potential conflict of interest in relation to this program/presentation.
Professor Alison Holmes
Grants/Research Support: Co-Supervisor (with the Department of Chemistry) of a Ph.D. fellowship funded through a collaborative programme involving industry partnerships. Industry partner: Shionogi (£15,000 per annum to Imperial College for a Ph.D. studentship)
Spouse/Partner: On the GSK Vaccine Scientific Advisory Board
Prof Paul Anantharajah Tambyah:
Grants/Research Support: Roche, Arcturus, Johnson and Johnson
Disclosure of Unlabeled Use
The International Society for Infectious Diseases requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. ISID does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Disclaimer
The International Society for Infectious Diseases presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The International Society for Infectious Diseases, and the former commercial supporter assume no liability for the information herein.
Copyright Information
Copyright © 2021 by the International Society for Infectious Diseases. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:
• The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
• Materials may not be published, uploaded, posted, transmitted (other than as set forth herein), without the International Society for Infectious Diseases' prior written permission.
Privacy Policy
The International Society for Infectious Diseases protects the privacy of personal and other information regarding participants and educational collaborators. The International Society for Infectious Diseases will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.
The International Society for Infectious Diseases maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.
Additional information regarding the International Society for Infectious Diseases Privacy Policy and ISID’s Knowledge Exchange and E-Learning Platform Privacy Policy can be viewed at https://isid.org/privacy-policy/
|
ACCREDITED ACTIVITY
The Impact of COVID-19 on Global Infectious Diseases - 2022
|
|
